12 unknown. 12 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Unknown 12 |
| Phase 1 | 3 | Unknown 3 |
Follow Immunoblastic Lymphadenopathy: new trials by email Literature Review of Immunoblastic Lymphadenopathy trials Research Report on Immunoblastic Lymphadenopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL mitoxantrone liposome 16 and azacitidine, mitoxantrone liposome 18 and azacitidine, mitoxantrone liposome 20 and azacitidine - Angioimmunoblastic T-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huijing Wu | 30 | 2023-12-12 | 2024-01-25 |
| Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma Azacitidine, Chidamide - Angioimmunoblastic T-cell Lymphoma | Phase 2 | Unknown | Peking Union Medical College Hospital | 20 | 2022-01-01 | 2022-01-05 |
| Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL Sintilimab, Chidamide - Angioimmunoblastic T-cell Lymphoma | Phase 2 | Unknown | Sun Yat-sen University | 83 | 2021-04-15 | 2021-04-05 |
| Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma Chidamide, Cyclophosphamide, Doxorubicin - Angioimmunoblastic T-cell Lymphoma | Phase 2 | Unknown | Ruijin Hospital | 23 | 2018-12-29 | 2022-04-20 |
| Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide) Chidamide - Angioimmunoblastic T-cell Lymphoma | Phase 2 | Unknown | Qingdao University | 30 | 2017-03-01 | 2017-09-25 |
| CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma anti-CD7 CAR-pNK cells - Acute Myeloid Leukemia, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-03-01 | 2016-12-06 |
| CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL CEOP/IVE/GDP chemotherapy regimen, CEOP chemotherapy regimen for 6 cycles - Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T Cell Lymphoma | Phase 2 | Unknown | Shandong Provincial Hospital | 106 | 2015-09-01 | 2020-03-10 |
| CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study Cyclophosphamide, Gemcitabine, Doxorubicin - Peripheral T-cell Lymphoma NOS, Anaplastic Large Cell Lymphoma, ALK-Negative | Phase 2 | Unknown | Royal Marsden NHS Foundation Trust | 87 | 2012-03-01 | 2018-03-15 |
| Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders anti-thymocyte globulin, busulfan, cyclophosphamide - Graft Versus Host Disease, Leukemia | Phase 2 | Unknown | Institut Paoli-Calmettes | 50 | 2008-01-01 | 2010-01-28 |
| Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma alemtuzumab, cyclophosphamide, doxorubicin hydrochloride - Lymphoma | Phase 1 / Phase 2 | Unknown | Toronto Sunnybrook Regional Cancer Centre | 84 | 2006-09-01 | 2013-09-20 |
| Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma cyclophosphamide, fludarabine phosphate, thalidomide - Lymphoma | Phase 2 | Unknown | Cancer Research UK | 37 | 2006-01-01 | 2013-08-26 |
| Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders anti-thymocyte globulin, cyclosporine, fludarabine phosphate - Leukemia, Lymphoma | Phase 2 | Unknown | Herbert Irving Comprehensive Cancer Center | 52 | 1998-04-01 | 2014-01-06 |
Lymphoma (4) · Lymphoma, Large-Cell, Anaplastic (4) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (4) · Enteropathy-Associated T-Cell Lymphoma (3) · Leukemia, Myeloid, Acute (3) · Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma, Non-Hodgkin (3) · Lymphoma, T-Cell (3) · Burkitt Lymphoma (2) · Congenital Abnormalities (2) · Hodgkin Disease (2) · Leukemia (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myeloid, Accelerated Phase (2)
Hemic and Lymphatic Diseases (12) · Immune System Diseases (12) · Immunoproliferative Disorders (12) · Lymphadenopathy (12) · Lymphatic Diseases (12) · Lymphoproliferative Disorders (12) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Hematologic Diseases (4) · Leukemia, Lymphoid (4) · Leukemia, Myeloid (3) · Lymphoma (3) · Lymphoma, B-Cell (3) · Lymphoma, Non-Hodgkin (3) · Lymphoma, T-Cell (3)
Cyclophosphamide (5) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (4) · Doxorubicin (3) · Vincristine (3) · fludarabine phosphate (3) · Antilymphocyte Serum (2) · Azacitidine (2) · Cyclosporine (2) · Methylprednisolone (2) · Mycophenolic Acid (2) · Prednisone (2) · Alemtuzumab (1) · Busulfan (1) · Cisplatin (1) · Flow Cytometry (1)
Cancer Research UK (1) · Herbert Irving Comprehensive Cancer Center (1) · Huijing Wu (1) · Institut Paoli-Calmettes (1) · Peking Union Medical College Hospital (1) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (1) · Qingdao University (1) · Royal Marsden NHS Foundation Trust (1) · Ruijin Hospital (1) · Shandong Provincial Hospital (1) · Sun Yat-sen University (1) · Toronto Sunnybrook Regional Cancer Centre (1)
China (7) · United Kingdom (2) · Canada (1) · France (1) · United States (1)
Claudius Rudin, MD (1) · David Cunningham, MD FRCP (1) · David G. Savage, MD (1) · Didier Blaise, MD (1) · Huijing Wu (1) · Lin Yang, Ph.D. (1) · Rena Buckstein, MD (1) · Wei Zhang, Dr (1) · Weili Zhao, MD. PhD (1) · Xin Wang, PhD (1)